TORONTO — Ranbaxy Pharmaceuticals is the latest drug maker to pull all of its prescription ranitidine products from the Canadian market as Health Canada continues its investigation into an impurity known as N-nitrosodimethylamine (NDMA) in the drugs.
Accord…

Click here to view the original article.